Ογ½ΆΚΣΖ΅

Tsewang Tashi
( out of 117 reviews )

Tsewang Tashi, MD

Languages spoken: Tibetan, English, Mandarin Chinese, French, Hindi, Urdu

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
Salt Lake City
801-585-0236

South Jordan Health Center

South Jordan
801-213-4500

VA - Building #14

Hematology/Oncology
Salt Lake City
801-582-1565

  • Dr. Tsewang Tashi joined the Ογ½ΆΚΣΖ΅ of Utah faculty after completing his hematology/oncology fellowship in 2015. He received his medical degree from Chang Gung Ογ½ΆΚΣΖ΅, Taiwan, and completed his internal medicine residency both in Taiwan, and in the US from Creighton Ογ½ΆΚΣΖ΅ Medical Center, Omaha, NE. Early in his career during fellowship, he has been involved in research with Dr. Josef Prchal on high altitude genetic adaptation, hypoxia signaling and molecular genetics of myeloproliferative neoplasms.

    His research and clinical interest lies in myeloid malignancies and currently sees and manages patients with myeloproliferative neoplasms, including systemic mastocytosis, and acute leukemias, both at the Huntsman Cancer Institute and serving the veterans at the George E. Whalen VA Medical Center in Salt Lake City. He established and currently leads the Mastocytosis Program at the Huntsman Cancer Hospital, which has been designated as Mastocytosis Center of Excellence. He also runs several clinical trials as the principal investigator in polycythemia vera, essential thrombocythemia, systemic mastocytosis and acute leukemia.

    At the VA Medical Center, he is one of the lead hematologists and cares for all the veterans with acute leukemias, myelodysplastic syndromes and myeloproliferative neoplasms that are referred to Salt Lake City VA from different parts of the Intermountain West. He also leads several research projects.

    To schedule an appointment New Mastocytosis Patients: 801-587-4630. New MPN Patients: (801)646-4122 Returning patients: 801-585-2626 or schedule through MyChart.

    For questions regarding our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist (801) 587-4630.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    4.9 /5
    ( out of 117 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    March 27, 2025
    HUNTSMAN CANCER CENTER

    Dr Tasewang, Is a great Dr. He listened and explained thing extremely well. He let me tape the conversation, I don't remember very well. I really appreciated that. Thank You Dr. Tashi

    March 20, 2025
    SOUTH JORDAN HEALTH CENTER

    Dr. Tashi has done a great job of managing my lymphoma! His treatment plan has and is working perfectly and he makes me feel at ease with my condition.

    February 28, 2025
    SOUTH JORDAN HEALTH CENTER

    Caring and thoughtful

    February 28, 2025
    HUNTSMAN CANCER CENTER

    Highly Recommend

    February 21, 2025
    HUNTSMAN CANCER CENTER

    Dr Tashi cares very much for his patients and has been a rock-solid advocate for my health-care journey. He has not just taken an interest in my medical needs, but takes the time to work with and for me to accomodate my schedule needs. I appreciate most that he treats me with compassion and reassurance, and hears my concerns, answering with honest answers even if they may be hard for me to hear. I'm so grateful to be his patient.

    February 21, 2025
    HUNTSMAN CANCER CENTER

    Dr Tashi is a God send to me. He listens, educates, explains and never makes me feel like he is in a hurry. He is present in thought and is always including me in the discussion of my best treatment plans.

    February 06, 2025
    HUNTSMAN CANCER CENTER

    Tashi is a wonderful doctor charismatic and respectful. Highly informative

    January 16, 2025
    HUNTSMAN CANCER CENTER

    Dr. Tashi is very experienced, thorough, and informative. He truly makes you feel at ease. He's an expert in his area of expertise

    December 01, 2024
    (HUNTSMAN) SOUTH JORDAN HEALTH CENTER

    The personal and professional treatment I received from Dr Tashi got me the new medication I needed for treatment of my PV cancer. He went above and beyond to secure this medication for me. Thank you Dr Tashi.

    See More Patient Comments

  • Dr. Tsewang Tashi joined the Ογ½ΆΚΣΖ΅ of Utah faculty after completing his hematology/oncology fellowship in 2015. He received his medical degree from Chang Gung Ογ½ΆΚΣΖ΅, Taiwan, and completed his internal medicine residency both in Taiwan, and in the US from Creighton Ογ½ΆΚΣΖ΅ Medical Center, Omaha, NE. Early in his career during fellowship, he has been involved in research with Dr. Josef Prchal on high altitude genetic adaptation, hypoxia signaling and molecular genetics of myeloproliferative neoplasms.

    His research and clinical interest lies in myeloid malignancies and currently sees and manages patients with myeloproliferative neoplasms, including systemic mastocytosis, and acute leukemias, both at the Huntsman Cancer Institute and serving the veterans at the George E. Whalen VA Medical Center in Salt Lake City. He established and currently leads the Mastocytosis Program at the Huntsman Cancer Hospital, which has been designated as Mastocytosis Center of Excellence. He also runs several clinical trials as the principal investigator in polycythemia vera, essential thrombocythemia, systemic mastocytosis and acute leukemia.

    At the VA Medical Center, he is one of the lead hematologists and cares for all the veterans with acute leukemias, myelodysplastic syndromes and myeloproliferative neoplasms that are referred to Salt Lake City VA from different parts of the Intermountain West. He also leads several research projects.

    To schedule an appointment New Mastocytosis Patients: 801-587-4630. New MPN Patients: (801)646-4122 Returning patients: 801-585-2626 or schedule through MyChart.

    For questions regarding our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist (801) 587-4630.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Associate Professor (Clinical)
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Graduate Training Master of Science in Clinical Investigation - Ογ½ΆΚΣΖ΅ of Utah M.S.C.I
    Fellowship Hematology/Oncology - Ογ½ΆΚΣΖ΅ of Utah Fellow
    Residency Internal Medicine - Creighton Ογ½ΆΚΣΖ΅ Resident
    Residency Internal Medicine - Pingtung Christian Hospital Resident
    Internship Internal Medicine - MacKay Memorial Hospital Intern
    Professional Medical Medicine - Chang Gung Ογ½ΆΚΣΖ΅ School of Medicine M.D.

    Selected Publications

    Journal Article

    1. Yacoub A, Abu-Zeinah G, Qin A, Tashi T, Dana W, Shih WJ, Zagrijtschuk O, Tsai CY, Geller R, Komatsu N, Mesa R, Gill H (2025). PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera. Ann Hematol. ()
    2. Li P, Alnoor FNU, Xie W, Williams M, Feusier J, Ding Y, Zhao X, Zheng G, Zhao C, Zieske AW, Zu Y, Raess PW, Tantravahi S, Osman A, Patel AB, Tashi T, Patel JL, Matynia AP, Menon MP, Miles RR, Jacobsen JR, George TI, Sborov DW, Szankasi P, Rindler P, Close D, Ohgami RS (2024). Rapid growth of acquired UBA1 mutations predisposes male patients to low-risk MDS. Leukemia, 39(1), 248-256. ()
    3. Gotlib J, Castells M, Elberink HO, Siebenhaar F, Hartmann K, Broesby-Olsen S, George TI, Panse J, Alvarez-Twose I, Radia DH, Tashi T, Bulai Livideanu C, Sabato V, Heaney M, Van Daele P, Cerquozzi S, Dybedal I, Reiter A, Pongdee T, Barete S, Ustun C, Schwartz L, Ward BR, Schafhausen P, Vadas P, Bose P, DeAngelo DJ, Rein L, Vachhani P, Triggiani M, Bonadonna P, Rafferty M, Butt NM, Oh ST, Wortmann F, Ungerstedt J, Guilarte M, Taparia M, Kuykendall AT, Arana Yi C, Ogbogu P, Gaudy-Marqueste C, Mattsson M, Shomali W, Giannetti MP, Bidollari I, Lin HM, Sulllivan E, Mar B, Scherber R, Roche M, Akin C, Maurer M (2023). Avapritinib versus Placebo in Indolent Systemic Mastocytosis. NEJM Evid, 2(6), EVIDoa2200339. ()
    4. Tashi T, Yu J, Pandya S, Dieyi C, Scherber R, Parasuraman S (2023). Trends in overall mortality among US veterans with primary myelofibrosis. BMC Cancer, 23(1), 48. ()
    5. Chuah YY, Tashi T, Kuo CJ (2022). An unexpected cause of Cullen's sign: rupture of hepatocellular carcinoma. Br J Hosp Med (Lond), 83(11), 1. ()
    6. Verstovsek S, Mesa R, Mascarenhas J, Tashi T, Shih W, Sato T, Urbanski R, Zagrijtschuk O, Zimmerman C (2022). MPN-546 A Single-Arm Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in North American Adults With Essential Thrombocythemia. Clin Lymphoma Myeloma Leuk, 22 Suppl 2, S342-S343. ()
    7. Feusier JE, Arunachalam S, Tashi T, Baker MJ, VanSant-Webb C, Ferdig A, Welm BE, Rodriguez-Flores JL, Ours C, Jorde LB, Prchal JT, Mason CC (2021). Large-Scale Identification of Clonal Hematopoiesis and Mutations Recurrent in Blood Cancers. Blood Cancer Discov, 2(3), 226-237. ()
    8. Gangaraju R, Song J, Kim SJ, Tashi T, Reeves BN, Sundar KM, Thiagarajan P, Prchal JT (2019). Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia. Blood Adv, 4(6), 1115-1130. ()

    Review

    1. Tashi T, Deininger MW (2023). Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms. [Review]. Immunol Allergy Clin North Am, 43(4), 723-741. ()
    2. Tashi T (2022). Hematocrit, White Blood Cells, and Thrombotic Events in the Veteran Population With Polycythemia Vera. [Review]. Fed Pract, 39(Suppl 2), S43-S46. ()

    Case Report

    1. Chuah YY, Tashi T, Lee YY, Fu TY, Shih CA (2020). Enteropathy-associated T-cell Lymphoma (EATL) with intracranial metastasis : a rare and dismal condition. Acta Gastroenterol Belg, 83(1), 77-80. ()

    Editorial

    1. Song J, Tashi T, Prchal JT (2019). Editorial Comment on: Inhibition of Suicidal Erythrocyte Death by Chronic Hypoxia by Tang et al. (From: Tang F, Feng L, Li R, Wang W, Liu H, Yang Q, Ge R-L. High Alt Med Biol 2019;20:112-119; DOI: 10.1089/ham.2017.0159). High Alt Med Biol, 20(2), 120-121. ()

  • News & Podcasts

    Huntsman Cancer Institute News